Summary: Seres Therapeutics began its Phase 1b placebo controlled clinical trial on Dec 14, 2015, for SER-287, which is the first drug aimed at the microbiome for a non-infectious, chronic condition, ulcerative colitis (UC). This is the first IBD microbiome drug that actually targets the constituents of the microbiome. This approach treats chronic disease without suppressing the body’s immune response. Instead, specific strains of bacteria are introduced that re-balance the billions of different types of bacteria that are in the digestive tract, which then increases immunity and manages the disease. Instead of being immunosuppressive, this treatment targets the root cause of UC which is gut dysbiosis, increasing immunity. SER-287 clinical trial is currently recruiting participants if you are interested; contact information is below.
SUMMARY: Aggressive Preventative Medicine means preserving the microbiome you have and restoring any loss incurred. See how far that thought goes with your doctor! Diet really does work to alter the microbiome and can help to restore loss of microbiome; for example, fermented kimchi actually positively impacted metabolic syndrome factors including systolic and diastolic blood pressures, percent body fat, fasting glucose, and total cholesterol.
⇒⇒ This post teaches how to reduce the loss of microbiome diversity and restore such – crowding out concept.